Ceryvyn Therapeutics-ADRCYVNY
13F holders, Q3 2025 (September 30)6holders −2
0new positions
1sold out
1famous investor
$0.01avg. 13F price*
At the end of Q3 2025, 6 institutions reported holding Ceryvyn Therapeutics-ADR (CYVNY) in their 13F filings, down 2 from Q2 2025. 0 opened new positions and 1 sold out. The largest holders were UBS Group AG ($62K), Morgan Stanley ($3K) and HSBC Holdings PLC ($10). One famous investor held it Israel Englander (0.0% of Millennium Management's portfolio).
- Company
- Ceryvyn Therapeutics-ADR
- Filed as
- OPTHEA LTD (Q3 2025)
- CUSIP
- 68386J208
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $0 |
All 13F filers, Q2 2025 → Q3 2025: 10,300 shares bought and 5,954 shares sold, net +4,346 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| UBS Group AG | 0.00% | Add +132.5% | 18,073 | $62K |
| Morgan Stanley | 0.00% | No change | 765 | $3K |
| HSBC Holdings PLC | 0.00% | No change | 105,939 | $10 |
| Baker Bros. Advisors LP | 0.00% | No change | 2,087,320 | $0 |
| Millennium Management | 0.00% | No change | 48,329 | $0 |
| Regal Partners Ltd | 0.00% | No change | 5,193,688 | $0 |
"% of holder's portfolio" is CYVNY's weight in each manager's 13F, not the share of Ceryvyn Therapeutics-ADR the manager owns.